Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486356 · ClinicalTrials.gov registry record · Phase 1
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00486356 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 46 participants.
The verdict
NCT00486356, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.
Interventions
- GENETIC microarray analysis
- DRUG carboplatin
- DRUG capecitabine
- DRUG epirubicin hydrochloride
- GENETIC polymorphism analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2004-10-01 |
| Est. Completion | 2010-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00486356
The ClinicalTrials.gov registry entry for NCT00486356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00486356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00486356 about?
NCT00486356 is a clinical study titled "Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer". RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00486356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2004-10-01. Estimated completion is 2010-01-01.
What interventions are being tested in trial NCT00486356?
The interventions under investigation include: microarray analysis (GENETIC), carboplatin (DRUG), capecitabine (DRUG), epirubicin hydrochloride (DRUG), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00486356?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.